Volta Labs, Inc.
-50%
est. 2Y upside i
Unlocking the utility of genomics for the world.
Rank
#66
Sector
Biotechnology
Est. Liquidity
~4Y
Data Quality
Data: MediumVolta Labs operates in a high-growth genomics market with a cutting-edge digital fluidics platform and a sequencer-agnostic approach, which are strong upside drivers.
Last updated: March 10, 2026
Volta Labs achieves significant market penetration with its Callisto platform and expands its application portfolio, securing major partnerships that drive revenue to ~$45M by 2028. This strong growth and differentiation justify a $450M valuation, providing a 350% upside for common shareholders.
Volta Labs continues to grow steadily, capturing a meaningful share of the NGS sample preparation market. Revenue reaches ~$30M by 2028, and the company is acquired or IPOs at a $360M valuation, representing a 260% upside.
Incumbent genomics players launch highly competitive automated sample preparation solutions, or market adoption is slower than expected. Revenue stalls at ~$15M, leading to a down round or acquisition at a valuation of $25M, resulting in a -75% downside for common shareholders due to liquidation preferences.
Preference Stack Risk
highFunding Intensity
38%Investors hold $25M in liquidation preferences. In an exit at $100M, common shareholders would receive $75M.
Dilution Risk
highAs a Series A company, Volta Labs will likely undergo at least one to two more significant funding rounds, leading to further dilution for existing equity holders.
Secondary Liquidity
noneThere is no indication of active secondary markets or tender offers for Volta Labs' equity at this stage.
Questions to Ask at the Interview
Strategic questions based on Volta Labs, Inc.'s data — designed to show you've done your homework.
- 1
“Given the 'medium' incumbent threat from major players like Illumina and PacBio, how is Volta Labs planning to maintain its competitive moat and prevent these giants from developing or acquiring similar technologies?”
- 2
“With current revenue at ~$9M and a significant TAM, what is the most aggressive yet realistic growth trajectory for revenue over the next 2-3 years, and what specific milestones are critical to achieving it?”
- 3
“Considering the Series A funding and the preference stack, what is the company's anticipated timeline and strategy for a liquidity event, and how is employee equity being structured to ensure meaningful returns for common shareholders?”
Community
Valuation Sentiment
Our model estimates -50% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.